Yahoo
NasdaqCM - Delayed Quote USD

Adial Pharmaceuticals, Inc. (ADIL)

2.8500 -0.1300 (-4.36%)
At close: June 15 at 4:00:01 PM EDT
2.8448 -0.0052 (-0.18%)
Pre-Market: 8:30:01 AM EDT
Chart Range Bar
Loading chart for ADIL
  • Previous Close 2.9800
  • Open 3.1200
  • Bid 2.9300 x 100
  • Ask 3.0000 x 100
  • Day's Range 2.7000 - 3.1200
  • 52 Week Range 1.3100 - 19.0000
  • Volume 246,233
  • Avg. Volume 462,636
  • Market Cap (intraday) 6.237M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -4.8900
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.00

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

www.adial.com

5

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 6/15/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ADIL
48.18%
S&P 500 (^GSPC)
10.35%

1-Year Return

ADIL
67.43%
S&P 500 (^GSPC)
26.39%

3-Year Return

ADIL
98.18%
S&P 500 (^GSPC)
70.69%

5-Year Return

ADIL
99.83%
S&P 500 (^GSPC)
77.89%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -2.02M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-2M
-2M
-1M
-500K
0

Analyst Insights

View More

Analyst Price Targets

8.00
8.00 Average
2.8500 Current
8.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/15/2026
Analyst LUCID CAPITAL MARKETS
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 6

Statistics

View More

Valuation Measures

Annual
As of 6/15/2026
  • Market Cap

    6.24M

  • Enterprise Value

    1.65M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.68

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -110.91%

  • Return on Equity (ttm)

    -265.94%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.77M

  • Diluted EPS (ttm)

    -4.8900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.58M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.91M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.8500 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: